Imaging neuroendocrine tumours with radionuclide techniques

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmacology

Background:

• Neuroendocrine tumors (NETs) represent a rare and heterogeneous group of neoplasms.
• NETs exhibit variable clinical presentations influenced by hormone secretion and mass effects.
• Accurate diagnosis, staging, and treatment of NETs rely on various imaging modalities.

Purpose of the Study:

• To review the role of functional imaging in diagnosing and staging neuroendocrine tumors (NETs).
• To discuss the application of single photon emission computed tomography (SPECT) and positron emission tomography (PET) radiopharmaceuticals in NET imaging.
• To highlight the importance of radionuclide imaging in the management of NETs.

Main Methods:

• Review of current literature on functional imaging techniques for NETs.
• Focus on SPECT and PET radiopharmaceuticals and their mechanisms of action.
• Analysis of the diagnostic and staging capabilities of different imaging agents.

Main Results:

• Radionuclide imaging, including SPECT and PET, is crucial for NET diagnosis and staging.
• Various radiopharmaceuticals target different cellular mechanisms for NET visualization.
• Functional imaging provides essential information for treatment planning.

Conclusions:

• Functional imaging with SPECT and PET plays a pivotal role in the comprehensive management of neuroendocrine tumors.
• The choice of radiopharmaceutical is critical and depends on the specific NET characteristics and uptake mechanisms.
• Continued advancements in radiopharmaceuticals enhance the diagnostic accuracy and therapeutic guidance for NET patients.